-
Company Profile
![]()
Exscientia Plc – Company Profile
Exscientia Plc (Exscientia) is an artificial intelligence-driven pharma tech company committed to discovering, designing, and developing drugs. The Company’s AI process is comprised of five elements, including Precision Target, Precision Design, Precision Experiment, Precision Medicine and Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Exscientia's advanced biophysical and x-ray techniques provide the experimental underpinnings for AI-design. The company gets high-precision information from viable patient tissue, screened...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-4318 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EXS-4318 in Inflammation Drug Details:EXS-4318 is under development for the treatment of unspecified immunologic disorders, Inflammation,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-4318 in Autoimmune Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EXS-4318 in Autoimmune DisordersDrug Details:EXS-4318 is under development for the treatment of unspecified immunologic disorders, Inflammation,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EXS-617 in Epithelial Ovarian Cancer Drug Details: EXS-617 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EXS-617 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: EXS-617 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Colorectal Cancer Drug Details: EXS-617 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Pancreatic Cancer Drug Details: EXS-617 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Solid Tumor Drug Details: EXS-617 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Non-Small Cell Lung Cancer Drug Details: EXS-617 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...
-
Company Insights
NewSanofi S.A – Digital Transformation Strategies
 Sanofi Digital Transformation Strategies Report Overview Sanofi S.A. (Sanofi) has been focusing on using artificial intelligence, cloud, virtual reality and big data to digitally transform its operations. The annual ICT spending of Sanofi was estimated at $1.1 billion for 2023. A major share of this spending is earmarked for acquiring software, ICT services and consulting services from vendors. Sanofi is a France-based multinational life sciences company. It focuses on the research & development, manufacture, and marketing of a wide range...
-
Thematic Analysis
![]()
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Company Insights
Bayer AG – Digital Transformation Strategies
Bayer implemented a five-year global IT strategy to drive its digital business transformation by aligning itself to emerging technologies like cloud, IoT, and AI among others. The annual ICT spending of Bayer was estimated at $2.3 billion in 2022. A major share of this spending is earmarked for acquiring hardware, network and communications, and software from vendors. Bayer is a life science company engaged in research, development, manufacture, and supply of products in healthcare and agriculture. Total ICT Spending 2022...
-
Company Insights
Exscientia Ltd. – Tech Innovator Profile
Exscientia Ltd (Exscientia) is a company that automates the drug discovery and design process, leveraging artificial intelligence (AI) and big data technologies. Its AI-driven platform, Centaur AI, enables researchers to design numerous target specific compounds and pre-assess their potency, and Experiment AI provides successful experimental outcomes. This report provides insights into Exscientia Ltd., including an overview of the company and its product offering, detailed coverage of its business model and operations, information on its funding and partnerships, and biographies of...
-
Thematic Analysis
![]()
State of the Biopharmaceutical Industry 2023
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you - Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months. Understand the most impactful emerging technologies - Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview...
-
Product Insights
![]()
Net Present Value Model: EXS-21546
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model EXS-21546 Drug Details EXS-21546 is under...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Report Bundle
58% offTech in Pharma – Report Bundle (7 Reports)
Tech in Pharma Bundle Report Overview Although the pharmaceutical industry had been slow to adopt technological innovations, the onset of COVID-19 has dramatically altered the situation. The latest technologies, Augmented Reality (AR), Big Data, and Artificial Intelligence (AI), among others, will assist pharmaceutical companies in speeding up the research and development process, creating personalized products, and conducting testing in novel ways. Finally, these technologies will improve healthcare effectiveness and efficiency thereby transforming the patient and provider experience. Explore actionable market...
-
Product Insights
Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. The Malaria pipeline market research report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and...
-
Product Insights
Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia pipeline market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.